研究疾病:
|
视疲劳
|
研究疾病代码:
|
|
Target disease:
|
Visual fatigue
|
Target disease code:
|
研究类型:
Study type:
|
干预性研究
Interventional study
|
研究设计:
Study design:
|
单臂
Single arm
|
研究所处阶段:
Study phase:
|
上市后药物
Post-marketing clinical trial
|
研究目的:
|
评价珍珠明目滴眼液(胶体溶液)治疗存在视疲劳的患者的疗效和安全性。
|
Objectives of Study:
|
To evaluate the efficacy and safety of Pearl Mingmu eye drops (colloidal solution) in the treatment of patients with visual fatigue.
|
药物成份或治疗方案详述:
|
使用珍珠明目滴眼液(胶体溶液)治疗,1 次 1~2 滴,滴入眼睑内,每日 5 次,为期 2 周。
|
Description for medicine or protocol of treatment in detail:
|
Pearl eye drops (colloidal solution) were used for treatment, 1 ~ 2 drops once, dropped into the eyelid, 5 times a day for 2 weeks.
|
纳入标准:
|
1.18岁及以上的患者,男女不限;
2.根据《视疲劳诊疗专家共识(2014年)》,诊断为轻度视疲劳,即用眼后常出现以下眼部症状:
(1)视觉障碍:近距离工作或阅读不持久,出现暂时性视物模糊或重影;
(2)眼部不适:眼胀、眼痛、眼干、眼烧灼感、流泪、眼痒、眼异物感及眼眶疼痛;
3.BUT<=10s或Schirmer I试验(无表面麻醉)<=10mm/5min;
4.0<角膜荧光素染色(CFS)<=5分;
5.经过充分知情愿意签署知情同意书并完成访视的患者。
|
Inclusion criteria
|
1 Patients aged 18 and over, male or female;
2.According to the consensus of experts on diagnosis and treatment of visual fatigue (2014), it is diagnosed as mild visual fatigue, that is, the following eye symptoms often occur after eye use:
(1)Visual impairment: short distance work or reading is not lasting, and temporary visual blur or ghosting occurs;
(2)Eye discomfort: eye swelling, eye pain, dry eyes, burning eyes, tears, itching eyes, foreign body in eyes and eye irritation, and orbital pain;
3.BUT<=10s or Schirmer I test (without surface anesthesia) <=10mm/5min;
4.0 < corneal fluorescein staining (CFS) <= 5 points;
5.Patients who are fully informed and willing to sign informed consent and complete the visit.
|
排除标准:
|
1.任一只眼为法定盲眼的患者;
2.入组前 1 个月内使用珍珠明目滴眼液(胶体溶液)或其他缓解视疲劳、治疗干眼症药物的患者;
3.诊断为重度视疲劳患者:存在全身症状,如易疲劳,头痛、头晕,记忆力减退,严重时甚至恶心、呕吐,并出现焦虑、烦躁以及其他神经官能症的症状;
4.眼部之外的疾病或因素(如精神和心理状态、女性月经期、更年期)导致的视疲劳;
5.对研究中预定使用的药物、辅料或检测(如珍珠液、冰片、玻璃酸钠、羟苯乙酯、荧光素)的任何组分有过敏史的患者;
6.入组前 2 周内或试验期间需联合眼部或全身的非甾体抗炎药、糖皮质激素、免疫抑制剂、对疗效评估有影响的物理治疗或眼部手术治疗的患者;
7.入组前 2 周内或试验期间需配戴隐形眼镜的患者;
8.曾接受过泪小点栓塞、泪小点封闭等封闭泪点治疗的患者;
9.患有需要治疗的活动性眼部炎症的患者;
10.计划妊娠、处于妊娠期或哺乳期的女性患者;
11.1 个月内曾参加或正在参加其他临床试验的患者;
12.有未被控制的全身疾病或其他原因,研究者判断认为不适合进入本研究的患者。
|
Exclusion criteria:
|
1.Patients whose eyes are legally blind;
2.Patients who used pearl eye drops (colloidal solution) or other drugs to relieve visual fatigue and treat dry eye within 1 month before enrollment;
3.Patients diagnosed with severe visual fatigue: there are systemic symptoms, such as fatigue, headache, dizziness, memory loss, even nausea and vomiting, anxiety, irritability and other neurological symptoms;
4.Visual fatigue caused by diseases or factors other than eyes (such as mental and psychological state, female menstruation and menopause);
5.Patients with a history of allergy to the drugs, excipients or any components of the test (such as pearl liquid, borneol, sodium hyaluronate, ethyl hydroxybenzene and fluorescein) scheduled for use in the study;
6.Patients who need to be treated with ocular or systemic non steroidal anti-inflammatory drugs, glucocorticoids, immunosuppressants, physical therapy or eye surgery that has an impact on the efficacy evaluation within 2 weeks before enrollment or during the trial;
7.Patients who need to wear contact lenses within 2 weeks before enrollment or during the trial;
8.Patients who have received lacrimal dot embolization, lacrimal dot closure and other lacrimal dot closure treatment;
9.Patients with active ocular inflammation requiring treatment;
10.Female patients with planned pregnancy, pregnancy or lactation;
11.Patients who have participated or are participating in other clinical trials within 1 month;
12.Patients with uncontrolled systemic diseases or other reasons that the investigator judges are not suitable for entering this study.
|
研究实施时间:
Study execute time:
|
从From
2021-08-11
至To
2021-12-31
|
征募观察对象时间:
Recruiting time:
|
从From
2021-09-13
至To
2021-11-01
|